Stocks · Sun Pharma vs Dr Reddy's
Sun Pharma vs Dr Reddy's: which pharma giant is the better stock in 2026?
Specialty-led US scale versus a generics-and-CDMO-led global diversification. A factual, signed comparison, informational and not a recommendation to buy or sell either stock.
The verdict
Sun Pharma is the larger pharma leader with a growing US specialty portfolio layered on generics, while Dr Reddy's is the generics and active-pharmaceutical-ingredient compounder with a growing CDMO arm and broad global diversification. Both are top Indian exporters; the call is specialty ambition versus generics-and-services breadth. As of 2026-06-16, the systematic read scores Sun Pharmaceutical Industries Limited 45 and Dr. Reddy's Laboratories Limited 61 on the BazaarBaazi Crack Score, an Edge Score of 66 out of 100 to Dr. Reddy's Laboratories Limited.
BazaarBaaziSource & method
The matchup, at a glanceSUNPHARMA 45 · DRREDDY 61
The Edge Score is a BazaarBaazi number for this matchup: 50 plus the gap between the two Crack Scores, capped at 100. 50 is a dead heat; the further above 50, the more decisively the systematic read favours the leader.
The case for eachStructural, not a tip
What each stock has going for it, factually. The Crack Score is the live systematic read; the edges are durable structural points, not forecasts.
The case for
Sun Pharmaceutical Industries Limited
Crack Score
45 / 100Mixed
Structural edges
- Largest Indian pharma company by scale and the broadest generic product basket.
- A US specialty pipeline targeting dermatology and ophthalmology at branded-drug margins.
- Depth across chronic and acute therapies that buffers the specialty ramp risk.
The case for
Dr. Reddy's Laboratories Limited
Crack Score
61 / 100Mixed
Structural edges
- API integration that gives cost and supply-chain resilience across its generics business.
- A CDMO business that adds a services revenue stream beyond pure product sales.
- Broad geographic diversification across regulated and emerging markets that smooths the US-cycle risk.
The live ratios, side by sideQ4 FY26 results · live spot
Valuation and quality ratios computed from each company's latest filed results times its live spot, the same engine as the fundamentals calculator. The price-derived ratios (P/E, P/B, yield) move with the market; the rest hold until the next results.
| Sun Pharmaceutical Industries Limited | Dr. Reddy's Laboratories Limited | |
|---|---|---|
| Return on equity | 13.8% | 11.4% |
| Net profit margin | 19.6% | 12.8% |
| EPS growth (YoY) | +4.8% | -24.3% |
| Debt to equity | 0.06 | 0.21 |
Stored from each company's filed results, as of 2026-06-16 and currency-checked; anything we could not verify is shown as n/a rather than guessed. Move the price and watch them react in the calculator.
The comparison, side by sideFactual
Sector, indicative market cap, the live Crack Score and stance, then the structural read on each business. The live valuation and quality ratios are in the table above; read any ratio against the sector and the company's own history.
| Sun Pharmaceutical Industries Limited | Dr. Reddy's Laboratories Limited | |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market capIndicative band, refreshed monthly. Read the live figure from the latest screen. | ~4.2 lakh cr | ~1.1 lakh cr |
| Crack Score | 45 / 100 | 61 / 100 |
| Systematic stance | Mixed | Mixed |
| What they do | India's largest pharma company, a broad generics book plus a growing US specialty pipeline across dermatology and ophthalmology. | A global generics maker with a large API and formulations business, a CDMO arm and sales across regulated and semi-regulated markets. |
| The moat | Scale, a specialty pipeline that targets branded-drug margins in the US, and one of the deepest generic product baskets. | API self-sufficiency, a global generics filings record and a CDMO arm that adds a services revenue stream. |
| Key driver 2026 to 2030 | Specialty-product ramp in the US, new launches and the pace of the generics cycle. | Generics approvals, API and CDMO revenue growth, and the pace of regulated-market expansion. |
| Main risk | US pricing pressure, regulatory inspections and the pace of specialty adoption. | US generic price erosion, API pricing cycles and plant-inspection outcomes. |
| Best suited to | The investor who wants the largest pharma name with US specialty optionality. | The investor who wants a globally diversified generics and services compounder. |
Compute the live valuation and quality ratios for either stock, or read the full signed verdict on SUNPHARMA and DRREDDY.
FAQ4 reader questions · AEO-eligible
The Sun Pharma vs Dr Reddy's call, distilled and schema-marked for AI Overview, Perplexity, and reader search.
Is Sun Pharma or Dr Reddy's a better stock?
Sun Pharma is the larger leader with a US specialty ambition, while Dr Reddy's is the globally diversified generics and CDMO compounder. Pick specialty-scale optionality versus generics-and-services breadth, and use the fundamentals calculator to read each company's current P/E and operating margin from the latest results before deciding.
What is Sun Pharma's US specialty play?
Sun Pharma has been building a US specialty portfolio focused on dermatology and ophthalmology, where branded-drug pricing and patent protection offer better margins than plain generics. The specialty pipeline is a multi-year build, and how fast launches ramp is the key variable the market watches.
What does CDMO mean for Dr Reddy's?
Contract Development and Manufacturing Organisation work means Dr Reddy's manufactures products for third-party innovator or generic companies, generating a services revenue stream alongside its own branded-generics business. This adds diversification and a less cyclical income source compared to pure generics launches.
Which pharma company is more exposed to the US market?
Both Sun Pharma and Dr Reddy's earn a significant share of revenue from the US generics market, which is their largest export destination. Sun Pharma's specialty build aims to move the US mix toward branded margins, while Dr Reddy's balances US generics with API and CDMO contributions. Read the latest US revenue splits from each company's results.
Other matchups
Hub
Compare stocks
All stock head-to-heads
Compare
TCS vs Infosys
Margin and scale versus the guidance-led growth read
Compare
HDFC Bank vs ICICI Bank
Post-merger liability franchise versus best-in-class return discipline
Compare
SBI vs HDFC Bank
Sovereign-backed scale and value versus private-sector return quality
Compare
Reliance vs Bharti Airtel
Diversified conglomerate optionality versus a focused premium-telecom compounder
Compare
HAL vs BEL
Platform-maker order book versus faster-converting defence electronics
Compare
Maruti vs Tata Motors
Mass-market distribution and margins versus JLR-led global cyclicality
Compare
ONGC vs Coal India
Oil-price-linked upstream versus a coal monopoly with a dividend floor
Compare
ICICI Bank vs PNB
Best-in-class private return profile versus a PSU asset-quality recovery
Compare
Sun Pharma vs Cipla
Specialty-led US scale versus a balanced India and respiratory franchise
Compare
Trent vs Titan
Fast-fashion retail expansion versus a jewellery-led consumer compounder
Compare
Bajaj Finance vs Bajaj Finserv
The pure-play lending compounder versus the diversified financial-services holding
Compare
Adani Enterprises vs Adani Ports
The incubator conglomerate versus the cash-generating ports infrastructure operator
Compare
Tata Steel vs JSW Steel
An integrated global steelmaker versus a domestic-led capacity grower
Compare
NTPC vs Power Grid
Generation capacity growth versus regulated transmission stability
Compare
SBI vs ICICI Bank
Sovereign-backed scale and value versus best-in-class private return discipline
Compare
HUL vs Nestle India
Broad home and personal-care breadth versus a focused packaged-foods franchise
Compare
HDFC Bank vs Kotak Bank
Post-merger liability scale versus a focused, capital-efficient compounder
Compare
Axis Bank vs ICICI Bank
A large-franchise turnaround versus best-in-class return and earnings quality
Compare
TCS vs Wipro
Margin and scale leadership versus a leaner, restructuring-led recovery
Compare
Infosys vs HCLTech
Guidance-led pure-services read versus a differentiated products-and-engineering mix
Compare
Nestle India vs Britannia
Focused multi-category brand power versus a biscuits-led margin compounder
Compare
ITC vs HUL
Conglomerate cash-and-value versus the broadest mass-market FMCG compounder
Compare
UltraTech Cement vs Grasim
The cement industry leader versus an Aditya Birla conglomerate with a cement holding and new businesses
Compare
SBI Life vs HDFC Life
Bancassurance scale through SBI versus a diversified product mix and balanced distribution
Compare
L&T vs Siemens India
A diversified domestic engineering conglomerate versus a focused industrial-technology franchise
Compare
Bajaj Auto vs Eicher Motors
Export-led volume scale and EV push versus the premium Royal Enfield franchise
Compare
DMart vs Trent
Everyday-value grocery scale versus a fast-fashion and format-expansion story
Compare
Asian Paints vs Pidilite
Decorative paint leadership versus a monopoly in construction adhesives
Compare
DLF vs Lodha
The oldest premium residential-and-commercial franchise versus the fastest-growing pan-India developer
Compare
Tata Power vs Adani Green
A diversified integrated power company versus a pure-play utility-scale renewables developer
Compare
TVS Motor vs Hero MotoCorp
A premium-and-premium-EV challenger versus the mass-market volume king
Compare
Shree Cement vs Ambuja Cements
The highest-margin, most efficient pure-play cement operator versus Adani-backed capacity scale
Compare
Cipla vs Zydus Lifesciences
A global respiratory and chronic-therapy generics leader versus an India-first FMCG-pharma blend with a biosimilar optionality
Compare
Tech Mahindra vs LTIMindtree
A telecom-anchored restructuring story versus a high-quality engineering-and-digital merger compounder
Compare
Tata Consumer vs Varun Beverages
A multi-category Tata group FMCG build-out versus the fastest-growing PepsiCo bottler franchise in the world
Compare
Adani Power vs NTPC
A private-sector capacity-growth story versus the sovereign-backed power PSU with a renewable pivot
Compare
Cholamandalam vs Shriram Finance
A diversifying vehicle and home-finance NBFC versus the dominant used-commercial-vehicle lender
Compare
Hindalco vs Vedanta
A globally integrated aluminium-and-copper compounder versus a diversified natural-resources conglomerate
Compare
Mahindra vs Hyundai India
The SUV-led domestic compounder with a farm and EV platform versus the premium Korean franchise in the Indian market
Compare
PFC vs REC Ltd
Broader power financing platform versus a focused utility lender
Compare
Bank of Baroda vs Canara Bank
Diversified PSU franchise with international presence versus a sharper domestic recovery
Compare
Wipro vs HCLTech
Turnaround execution potential versus a steadier IT services and products blend
Compare
Godrej Consumer Products vs Dabur
Personal care and home care momentum versus defensive staples and wellness breadth
Compare
IndusInd Bank vs Kotak Bank
Higher-beta recovery potential versus quality-first private banking franchise
Compare
BPCL vs GAIL India
Downstream petroleum and refining leverage versus gas transmission and utility infrastructure
Compare
Tata Steel vs JSPL
Integrated steel scale and global diversification versus a focused domestic metals execution story
Compare
Torrent Pharma vs Divi's Labs
Branded formulations franchise versus specialty API and custom manufacturing excellence
Compare
ABB India vs CG Power
Premium electrification and automation technology versus a capital goods recovery and execution story
Compare
Motherson vs Bosch India
Global multi-category auto-component scale versus premium engineering and technology in auto systems
Compare
Muthoot Finance vs Bajaj Finance
Specialist gold-backed lending versus a broad consumer and retail credit platform
Compare
Adani Energy Solutions vs Tata Power
Transmission and distribution network expansion versus an integrated utility and clean energy franchise